Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Conditions
Keywords
Non small cell lung cancer (NSCLC), Lung tumor in advanced phase
Brief summary
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death worldwide with 1.4 millions of deaths every years. Current standard therapies include platinum-containing drugs but at one year from diagnosis the survival rate is still low (30-40%) . The purpose of this study is to evaluate the role of a platinum-free drug, named Vinorelbine, administered by the so called metronomic schedule in order to prolong the progression free survival of patients.
Detailed description
Systemic therapy remains the mainstay of treatment of advanced stage NSCLC. Combination chemotherapy with a platinum-based regimen has emerged as standard therapy for patients with advanced stage disease. Observations supported by the findings of several clinical trial, established the notion that an efficacy plateau had been reached in advanced stage NSCLC patients treated with platinum-containing drugs. Recent phase III trials suggest the benefit of switch and continuing maintenance treatment with different drugs. As switched therapy, Vinorelbine has been selected on the base of its anti-mitotic role. In fact, the use of anti-mitotic drugs at lower dose but with higher frequency (metronomic schedule) seems to augment the anti-angiogenetic effect of this kind of drugs, thus augmenting the efficacy of the therapy. Therefore, the purpose of the current study is to evaluate the role of a switched maintenance with oral vinorelbine administered as a metronomic schedule in terms of Progression Free Survival (PFS) in advanced NSCLC patients with stable disease after first line platinum based chemotherapy.
Interventions
DRUGVinorelbine
Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
Sponsors
Regione Lombardia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed and dated approved ICF 2. Histologically or cytologically confirmed diagnosis NSCLC diagnosis 3. Stage IV (using AJCC 7th edition, or wet IIIb / IV using the 6th edition), or recurrent locally advanced disease not amenable to radiation or surgery with curative intent and not amenable to concurrent chemoradiation 4. Patients with stable disease, after four-six cycles of platinum-based chemotherapy as first line therapy. Patients with partial or complete response during first line chemotherapy according to RECIST criteria can be enrolled provided that they have stable disease at the study entry. 5. Patients who may have received adjuvant treatment (containing also vinorelbine) at least 6 mos before study entry 6. ECOG performance status 0-2 7. Adequate bone marrow reserve as measured by ANC ≥ 1500/mm3, hemoglobin ≥ 9 g/dL, platelet count ≥ 100,000/μL, ≥ 1 week after last transfusion of blood products and/or last dose of hematopoietic growth factor 8. Prothrombin time (PT) or INR or aPTT ≤ 1.5 x ULN 9. Calculated creatinine clearance ≥ 30 mL/min (Cockcroft and Gault Formula) 10. AST (SGOT) and ALT (SGPT) \< 2.5 x ULN, AST and ALT \< 5 x ULN (if documented liver metastases) 11. Serum bilirubin \< 2.0 mg/dL (patients with Gilbert's syndrome: serum bilirubin ≤ 3 x ULN 12. Alkaline phosphatase \< 2.5 x ULN (patients with documented liver or bone metastases, alkaline phosphatase ≤ 5 x ULN) 13. No other obvious related major organ toxicities which would compromise the patient's ability to participate in a clinical trial 14. Allowed prior radiation therapy for local or locally advanced disease providing that any clinically significant adverse effects associated with prior therapy have recovered to Grade 1 or less 15. Women of childbearing potential must have a negative serum pregnancy test and agree to use effective birth control during the trial and for 12 wks after the last treatment dose 16. Males must agree to use effective birth control for themselves or their partner during the trial and for 12 wks after the last treatment dose 17. Life expectancy of at least 12 wks 18. Male or female, age ≥18
Exclusion criteria
1. Patients who have received induction therapy with platinum obtaining progressive disease 2. Patients who can benefit from pemetrexed maintenance treatment (adenocarcinoma and ECOG PS 0-1) should be excluded. Enrollment in the trial is permitted for patients who refuse maintenance with pemetrexed or in case of clinical contraindications to pemetrexed therapy (for example renal failure, creatinine clearance ≤ 45 mL/min) 3. Patients who have received, or are scheduled to receive, single agent or combination therapy consisting of chemotherapy, targeted, biological, investigational, hormonal as maintenance treatment 4. Previous treatment for metastatic disease with chemotherapy containing oral or i.v. vinorelbine formulation 5. Last dose of induction chemotherapy \< 21 d prior to randomization or \> 42 d prior to randomization 6. Concurrent treatment with other experimental drugs. 7. Radiation therapy within 3 wks prior to randomization (palliative radiation therapy is allowed, provided that sites of bone marrow production, i.e., iliac crests are not in the radiation field) 8. Major surgery within 4 wks prior to first study drug administration 9. Active central nervous system (CNS) metastatic disease. Patients with stable CNS disease following completion of radiation therapy and/or surgery are eligible 10. Active or chronically recurrent bleeding (e.g., active peptic ulcer disease) 11. Malabsorption syndrome or any other disorder affecting gastrointestinal absorption 12. Clinically significant infection 13. Clinically significant cardiovascular disease or condition including: congestive heart failure (CHF) requiring therapy, need for anti-arrhythmic therapy for a ventricular arrhythmia, severe conduction disturbance, angina pectoris requiring therapy, medically uncontrolled hypertension per the Investigator's discretion, myocardial infarction within 6 mos prior to first study drug administration, New York Heart Association Class II, III, or IV cardiovascular disease 14. Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator 15. History of neoplasm other than curatively treated non-melanoma skin cancer or other carcinoma in situ, that has been resected, unless that prior malignancy was diagnosed and definitely treated at least 3 ys previously with no subsequent evidence of recurrence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Assessed at every 2 cycles (6 wks), 28d after last dose intake and, for patients discontinuing vinolbine for reason other than PD, every 6 wks during Follow Up, up to 18 mos after the enrollment of the Last Patient (LPI) | PFS: defined as the time from the date of randomization to the date of first documentation of progression, or of death due to any cause, whichever comes first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Tumor Response Rate (ORR, CR+PR) | Assessed at every 2 cycles (6wks), 28d after last dose intake and, during Follow Up, every 3 mos except for patients discontinuing vinolbine for reason other than PD whose assessment is every 6 wks, up to 18 mos after LPI | ORR, CR+PR: defined as the proportion of patients with measurable disease at baseline achieving partial or complete overall best response according to RECIST version 1.1 criteria. |
| Duration of Response (only in patients in CR or PR) | Assessed every two cycles (6wks), 28d after last dose intake and, during Follow Up, every 3 mos except for patients discontinuing vinolbine for reason other than PD whose assessment is every 6 wks, up to 18 mos after LPI | Duration of Response (only in patients in CR or PR): defined as the time from the date of the first documentation of confirmed objective tumor response to the date of first documentation of objective tumor progression, objective tumor recurrence, or of death due to progressive disease, whichever comes first. |
| Overall Survival (OS) | Assessed at every cycle (3wks), 28d after last dose intake and, during Follow Up, every 3 mos except for patients discontinuing vinolbine for reason other than PD whose assessment is every 6 wks, up to 18 mos after LPI | OS: defined as the time from the date of randomization to the date of death from any cause or the last date the patient was known to be alive. |
| Quality of Life (QoL) according to EORTC QLC30, EORTC QOL-LC13 | Assessed at every 2 cycles (6wks), 28d after last dose intake and, for patients discontinuing vinolbine for reason other than PD, every 6 wks during Follow Up, up to 18 mos after LPI | — |
| Overall Safety Profile | Assessed at every cycle (3wks) and 28d after last dose intake up to 18 months after LPI | Overall Safety Profile, characterized by type, frequency, severity \[graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\], timing and relationship to study therapy of adverse events and laboratory abnormalities. |
| Duration of Post Progression Survival | Assessed at 28d after last dose intake and, during Follow Up, every 3 mos except for patients discontinuing vinolbine for reason other than PD whose assessment is every 6 wks, up to 18 mos after LPI | Duration of Post Progression Survival: defined as the time from the date of first documentation of objective tumor progression to the date of death from any cause or the last date the patient was known to be alive. |
Countries
Italy
Outcome results
None listed